공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 반려동물 의약품 시장 예측과 COVID-19의 영향(-2026년) : 적응증(감염증, 항생물질, 구충제, 백신, 통증), 동물 종류(개, 고양이, 말), 유통 경로(수의 병원, 진료소), 지역별

Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026

리서치사 MarketsandMarkets
발행일 2021년 04월 상품 코드 1000374
페이지 정보 영문 232 Pages
가격
US $ 4,950 ₩ 5,680,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,630,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,352,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,475,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 반려동물 의약품 시장 예측과 COVID-19의 영향(-2026년) : 적응증(감염증, 항생물질, 구충제, 백신, 통증), 동물 종류(개, 고양이, 말), 유통 경로(수의 병원, 진료소), 지역별 Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026
발행일 : 2021년 04월 페이지 정보 : 영문 232 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 반려동물 의약품 시장 규모는 예측기간 중 7.6%의 CAGR로 확대되고, 2021년 128억 달러에서 2026년에는 185억 달러 규모로 성장할 것으로 예측됩니다.

애완동물 사육자수 증가, 동물 건강 관리나 백신 접종이 중요시되는 경향, 동물용 헬스케어 제품에 대한 수요 증가, 선진 국가의 수의사수 증가, 소득수준 향상, 인수 공통 감염증 확대, 반려동물 사육두수 증가, 동물 질병 확대, 애완동물 보험에 대한 수요 증가 등 다양한 요인이 시장 성장을 추진하고 있습니다. 한편 새로운 항생물질 수가 한정되어 있는 점, 애완동물 케어 비용 상승, 항균제나 항생물질에 대한 내성 증가, 백신 보관 비용 상승 등의 과제가 시장 성장을 어느 정도 억제하고 있습니다.

세계의 반려동물 의약품(Companion Animal Pharmaceuticals) 시장을 조사했으며, 시장 및 제품 개요, 밸류체인, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 규제 상황, 특허 동향, 시장 규모 추정과 예측, 적응증·동물 종류·유통 경로·지역/주요 국가별 내역, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
    • 시장 과제

제6장 산업 분석

  • 산업 동향
  • Porter's Five Forces 분석
  • 규제 분석
  • 밸류체인 분석
  • 공급망 분석
  • 생태계 분석
  • COVID-19의 영향
  • 특허 분석

제7장 시장 분석과 예측 : 적응증별

  • 감염증
    • 구충제
    • 백신
    • 항생물질·항균제
    • 기타
  • 피부질환
  • 통증
  • 정형외과 질환
  • 행동장애
  • 기타

제8장 시장 분석과 예측 : 동물 종류별

  • 고양이
  • 기타

제9장 시장 분석과 예측 : 유통 경로별

  • 수의 병원
  • 수의 클리닉
  • 소매 약국

제10장 시장 분석과 예측 : 지역·주요 국가별

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 기타
  • 라틴아메리카
  • 중동 및 아프리카

제11장 경쟁 상황

  • 개요
  • 주요 기업의 전략
  • 주요 기업의 지역적 발자국
  • 기업의 제품 발자국
  • 상위 기업의 매출 점유율
  • 시장 점유율 분석
  • 시장 평가 체계
  • 경쟁 리더십 매핑
  • 스타트업 : 경쟁 리더십 매핑
  • 경쟁 상황과 동향

제12장 기업 개요

  • 주요 기업
    • ZOETIS INC.
    • MERCK & CO., INC.
    • BOEHRINGER INGELHEIM GMBH
    • ELANCO ANIMAL HEALTH INCORPORATED
    • CEVA SANTE ANIMALE
    • VIRBAC
    • VETOQUINOL S.A.
    • DECHRA PHARMACEUTICALS PLC
    • CHANELLE PHARMA
    • KYORITSU SEIYAKU
    • ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED
    • TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
    • HIPRA
    • NORBROOK HOLDINGS LIMITED
    • INOVET
  • 기타 기업
    • ENDOVAC ANIMAL HEALTH
    • ECO ANIMAL HEALTH GROUP PLC
    • INDIAN IMMUNOLOGICALS LTD.
    • ASHISH LIFE SCIENCE PVT. LTD.
    • LUTIM PHARMA PVT. LTD.

제13장 부록

KSM 21.04.27

The global companion animal pharmaceuticals market is projected to reach USD 18.5 billion by 2026

from USD 12.8 billion in 2021, at a CAGR of 7.6% during the forecast period. Companion animals play an important role in the lives of many, providing a sense of belonging and responsibility. Animal health products, especially pharmaceuticals, are the most widely used products for animal healthcare. They contribute significantly to the health and wellbeing of animals. Companion animal ownership and expenditure have witnessed a significant increase over the years. Pet owners are spending more per pet than ever before. The increasing number of people having pets, emphasis on animal healthcare and vaccination, increasing demand for animal healthcare products, increasing number of veterinary practitioners and their rising income levels in developed economies, increasing prevalence of zoonotic diseases, growth in companion animal adoption, increasing prevalence of animal diseases, and rising demand for pet insurance are some of the factors driving the growth of these markets. However, the limited number of new antibiotics, rising pet care costs, growing resistance to antimicrobials and antibiotics, and rising cost of vaccine storage are restraining the growth of this market to a certain extent.

"The dermatologic diseases segment to grow at the highest CAGR in the companion animal pharmaceuticals market, in the forecast period."

Based on the prescription of pharmaceuticals for a number of disorders prevailing in animals, the companion animal pharmaceuticals market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic diseases segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of arthritis, rising need for advanced orthopedic drugs, and growing pet population are some of the key factors driving the growth of this segment.

"The dogs segment holds the largest share in the animal type segment, in the forecast period."

Based on animal type, the companion animal pharmaceuticals market is segmented into dogs, cats, horses, and other companion animals. The dogs segment accounted for the largest market share in 2020. The large share of this segment is attributed to the increasing dog population and rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe.

"Veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market by distribution channel segment in the forecast period"

Based on the distribution channel, the global companion animal pharmaceuticals market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospitals segment is expected to grow at the highest CAGR during the forecast period. The higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries, are some of the key factors driving the growth of this segment.

"North America holds the largest share in the companion animal pharmaceuticals market, by region, in the forecast period"

In 2020, North America accounted for the largest share of the companion animal pharmaceuticals market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the well-established base of animal health industries, the high adoption of companion animals, rising incidence of parasitic infections, the large number of hospitals and clinics, growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is also expected to drive the growth of this market.

A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation: C-level-35%, Director Level-25%, and Others-40%
  • By Region: North America-45%, Europe-30%, Asia Pacific-20%, Latin America - 3%, Middle East & Africa-2%

The prominent players in the global companion animal pharmaceuticals market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Sante Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Research Coverage:

The report analyzes the market for various companion animal pharmaceuticals and their adoption pattern. It aims at estimating the market size and future growth potential of the global companion animal pharmaceuticals market and different segments such as indication, animal type, distribution channels, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
  • Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
    • TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primaries
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS
    • FIGURE 6 SUPPLY-SIDE ANALYSIS OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
    • FIGURE 7 MARKET ANALYSIS APPROACH
    • FIGURE 8 US: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
    • FIGURE 9 TOP-DOWN APPROACH
    • FIGURE 10 CAGR PROJECTIONS
    • FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2021-2026): IMPACT ON MARKET GROWTH & CAGR
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 RISK ASSESSMENT/LIMITATIONS
  • 2.7 COVID-19 HEALTH ASSESSMENT
  • 2.8 COVID-19 ECONOMIC ASSESSMENT
  • 2.9 ASSESSING THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
    • FIGURE 13 CRITERIA IMPACTING THE GLOBAL ECONOMY
    • FIGURE 14 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY

    • FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2021 VS. 2026 (USD MILLION)
    • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET

4 PREMIUM INSIGHTS

  • 4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
    • FIGURE 19 RISING PET POPULATION TO DRIVE MARKET GROWTH
  • 4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2020)
    • FIGURE 20 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020
  • 4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • 4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2019-2026)
    • FIGURE 22 NORTH AMERICA WILL CONTINUE TO DOMINATE THE COMPANION ANIMAL PHARMACEUTICALS MARKET DURING THE FORECAST PERIOD
  • 4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 23 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • TABLE 2 COMPANION ANIMAL PHARMACEUTICALS MARKET: IMPACT ANALYSIS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Growing prevalence of zoonotic diseases
    • TABLE 3 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013-2018)
      • 5.2.1.2 Rising demand for pet insurance with growing animal health expenditure
    • FIGURE 24 US: PET EXPENDITURE, 2010-2019 (USD BILLION)
    • FIGURE 25 US: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION)
      • 5.2.1.3 Growing investments by key players
      • 5.2.1.4 Initiatives by various government agencies and animal associations
      • 5.2.1.5 Growth in companion animal ownership rates
    • FIGURE 26 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Rising pet care costs
      • 5.2.2.2 Limited number of new product developments
      • 5.2.2.3 High storage cost of vaccines
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Lucrative growth opportunities in emerging markets
      • 5.2.3.2 Growing prevalence of animal diseases
      • 5.2.3.3 Technological advancements in manufacturing vaccines
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Stringent regulatory approval process for drugs
      • 5.2.4.2 Inadequate surveillance and reporting systems of vaccines
      • 5.2.4.3 Diversity of parasite species

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • 6.2.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTHCARE INDUSTRY
    • TABLE 4 MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017-2019)
    • 6.2.2 INNOVATIONS IN ANIMAL HEALTHCARE PRODUCTS
    • TABLE 5 INNOVATIVE ANIMAL PHARMACEUTICAL TRENDS
  • 6.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1 THREAT OF NEW ENTRANTS
    • 6.3.2 THREAT OF SUBSTITUTES
    • 6.3.3 BARGAINING POWER OF SUPPLIERS
    • 6.3.4 BARGAINING POWER OF BUYERS
    • 6.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.4 REGULATORY ANALYSIS
    • FIGURE 27 DEVELOPMENT AND APPROVAL PROCESS FOR COMPANION ANIMAL PHARMACEUTICAL PRODUCTS
    • TABLE 7 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
    • FIGURE 28 EUROPE: COMPANION ANIMAL PHARMACEUTICAL PRODUCTS APPROVAL PROCESS
  • 6.5 VALUE CHAIN ANALYSIS
    • FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
  • 6.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
  • 6.7 ECOSYSTEM ANALYSIS
    • 6.7.1 ECOSYSTEM ANALYSIS FOR THE COMPANION ANIMAL PHARMACEUTICALS MARKET
    • FIGURE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
  • 6.8 IMPACT OF COVID-19 ON THE COMPANION ANIMAL PHARMACEUTICALS MARKET
  • 6.9 PATENT ANALYSIS
    • 6.9.1 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
    • FIGURE 32 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015-2020)
    • 6.9.2 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS
    • FIGURE 33 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS PATENTS (2015-2020)
    • 6.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
    • FIGURE 34 TOP APPLICANT COUNTRIES FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015-2020)

7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION

  • 7.1 INTRODUCTION
    • TABLE 8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
  • 7.2 INFECTIOUS DISEASES
    • TABLE 9 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.2.1 PARASITICIDES
      • 7.2.1.1 Growing regulatory guidelines to prevent the spread of parasite-caused diseases is fueling the market growth
    • TABLE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.2.2 VACCINES
      • 7.2.2.1 Rising awareness among pet owners for vaccinating dogs and cats to drive market growth
    • TABLE 12 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
      • 7.2.3.1 Antibiotics and antimicrobials help combat clinical and subclinical diseases in animals
    • TABLE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2019-2026 (USD MILLION)
    • 7.2.4 OTHER COMPANION ANIMAL PHARMACEUTICALS
    • TABLE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMAL PHARMACEUTICALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 DERMATOLOGIC DISEASES
    • 7.3.1 GROWING CASES OF DERMATOLOGIC DISEASES HAVE INCREASED THE DEMAND FOR VETERINARY PHARMACEUTICALS
    • TABLE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 PAIN
    • 7.4.1 RISING PREVALENCE OF MUSCULOSKELETAL DISORDERS TO DRIVE SUPPORT MARKET GROWTH
    • TABLE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 ORTHOPEDIC DISEASES
    • 7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS AND THE INCREASING POPULATION OF OBESE PETS HAS INCREASED THE DEMAND FOR ORTHOPEDIC DRUGS
    • TABLE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 BEHAVIORAL DISORDERS
    • 7.6.1 GROWING AWARENESS AMONG PET OWNERS REGARDING BEHAVIORAL DISORDERS IS EXPECTED TO FUEL THE DEMAND FOR THESE DRUGS
    • TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.7 OTHER INDICATIONS
    • TABLE 19 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019-2026 (USD MILLION)

8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE

  • 8.1 INTRODUCTION
    • TABLE 20 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
  • 8.2 DOGS
    • 8.2.1 DOGS SEGMENT IS EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD
    • FIGURE 35 POPULATION OF PET DOGS IN INDIA (MILLION)
    • FIGURE 36 POPULATION OF PET DOGS GLOBALLY (MILLION)
    • TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 CATS
    • 8.3.1 GROWING RESEARCH ON FELINE HEALTH AND WELLBEING TO SUPPORT THE MARKET GROWTH
    • TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 HORSES
    • 8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES IN THE EQUINE POPULATION TO DRIVE MARKET GROWTH
    • TABLE 23 HORSE POPULATION, BY REGION, 2016-2019 (MILLION)
    • TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.5 OTHER COMPANION ANIMALS
    • TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019-2026 (USD MILLION)

9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
  • 9.2 VETERINARY HOSPITALS
    • 9.2.1 VETERINARY HOSPITALS ARE THE LARGEST AND FASTEST-GROWING SEGMENT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
    • TABLE 27 VETERINARY VISIT EXPENSES FOR CATS AND DOGS IN THE US
    • TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 VETERINARY CLINICS
    • 9.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH
    • TABLE 29 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2015 VS. 2019
    • TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 RETAIL PHARMACIES
    • 9.4.1 EASY ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTION AND OTC TO SUPPORT THE MARKET GROWTH
    • TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019-2026 (USD MILLION)

10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 32 COMPANION ANIMAL POPULATION, BY COUNTRY, 2020 (THOUSAND)
    • FIGURE 37 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
    • TABLE 33 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 38 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA
    • FIGURE 39 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 35 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 36 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 37 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 38 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 The US dominates the North American companion animal pharmaceuticals market
    • FIGURE 40 US: INCREASE IN PET EXPENDITURE, 2010-2019 (USD BILLION)
    • TABLE 39 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018
    • TABLE 40 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 41 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 42 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 43 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing pet adoption rate and rising animal health awareness to support market growth in Canada
    • TABLE 44 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 45 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 46 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 47 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 48 EUROPE: NUMBER OF VETERINARIANS, 2012-2018
    • TABLE 49 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 50 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 51 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 52 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 53 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany held the largest share of the European market in 2020
    • TABLE 54 GERMANY: COMPANION ANIMAL POPULATION, 2012-2018 (MILLION)
    • TABLE 55 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 56 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 57 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 58 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Growing pet ownership rates to drive market growth
    • TABLE 59 UK: COMPANION ANIMAL POPULATION, 2010-2018 (MILLION)
    • TABLE 60 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 61 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 62 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 63 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Presence of major players in the country is expected to propel the companion animal pharmaceuticals market
    • TABLE 64 FRANCE: COMPANION ANIMAL POPULATION, 2010-2018 (MILLION)
    • TABLE 65 FRANCE: NUMBER OF VETERINARIANS, 2014 VS. 2016 VS. 2018
    • TABLE 66 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 67 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 68 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 69 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.4 SPAIN
      • 10.3.4.1 Increasing animal health expenditure is propelling market growth in Spain
    • TABLE 70 SPAIN: COMPANION ANIMAL POPULATION, 2014-2018 (MILLION)
    • TABLE 71 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 72 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 73 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 74 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Growing animal healthcare expenditure to support market growth
    • TABLE 75 ITALY: COMPANION ANIMAL POPULATION, 2016-2018 (MILLION)
    • TABLE 76 ITALY: NUMBER OF VETERINARIANS, 2016 VS. 2019
    • TABLE 77 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 78 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 79 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 80 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 81 ROE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
    • TABLE 82 COMPANION ANIMAL POPULATION IN THE REST OF EUROPE, 2019 (MILLION)
    • TABLE 83 ROE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2016 VS. 2019
    • TABLE 84 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 85 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 86 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 87 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 41 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
    • TABLE 88 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 China dominates the companion animal pharmaceuticals market
    • FIGURE 42 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)
    • TABLE 93 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 94 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 95 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 96 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Rising demand for imported breeds is driving pet adoption rates in the country
    • TABLE 97 JAPAN: NUMBER OF VETERINARIANS, 2016 VS. 2019
    • TABLE 98 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 99 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 100 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 India is an untapped market with large growth potential in companion animal pharmaceuticals
    • FIGURE 43 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)
    • TABLE 102 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 103 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 104 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 105 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.4.4 SOUTH KOREA
      • 10.4.4.1 Rising pet population and growing awareness about animal health to support market growth
    • TABLE 106 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 107 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 108 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • FIGURE 44 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018-2025 (MILLION)
    • TABLE 110 ROAPAC: NUMBER OF VETERINARIANS, 2012-2019
    • TABLE 111 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 112 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 113 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 114 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 RISING POOL OF SKILLED VETERINARIANS AND GROWING PET HEALTH EXPENDITURE TO DRIVE THE MARKET GROWTH
    • TABLE 115 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICAN COUNTRIES, 2016 VS. 2019
    • TABLE 116 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 117 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 118 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 119 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING POPULATION OF COMPANION ANIMALS TO PROPEL MARKET GROWTH
    • TABLE 120 AFRICA: NUMBER OF VETERINARIANS, 2012 VS. 2017 VS. 2019
    • TABLE 121 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019-2026 (USD MILLION)
    • TABLE 122 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019-2026 (USD MILLION)
    • TABLE 124 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO FEBRUARY 2021
  • 11.3 GEOGRAPHICAL FOOTPRINT OF THE MAJOR PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET
    • FIGURE 45 GEOGRAPHIC REVENUE MIX: COMPANION ANIMAL PHARMACEUTICALS MARKET (2020)
  • 11.4 COMPANY PRODUCT FOOTPRINT
    • FIGURE 46 PRODUCT PORTFOLIO ANALYSIS: COMPANION ANIMAL PHARMACEUTICALS MARKET
  • 11.5 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS
    • FIGURE 47 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2015-2019)
  • 11.6 MARKET SHARE ANALYSIS
    • FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2020
  • 11.7 MARKET EVALUATION FRAMEWORK
    • FIGURE 49 MARKET EVALUATION FRAMEWORK: ACQUISITIONS-THE MOST WIDELY ADOPTED STRATEGY
  • 11.8 COMPETITIVE LEADERSHIP MAPPING
    • 11.8.1 STARS
    • 11.8.2 EMERGING LEADERS
    • 11.8.3 PERVASIVE PLAYERS
    • 11.8.4 PARTICIPANTS
    • FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
  • 11.9 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
    • 11.9.1 PROGRESSIVE COMPANIES
    • 11.9.2 DYNAMIC COMPANIES
    • 11.9.3 STARTING BLOCKS
    • 11.9.4 RESPONSIVE COMPANIES
    • FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
  • 11.10 COMPETITIVE SITUATION AND TRENDS
    • 11.10.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 125 PRODUCT LAUNCHES & APPROVALS
    • 11.10.2 EXPANSIONS
    • TABLE 126 EXPANSIONS
    • 11.10.3 ACQUISITIONS
    • TABLE 127 ACQUISITIONS
    • 11.10.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • TABLE 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, MnM View)**
    • 12.1.1 ZOETIS INC.
    • TABLE 129 ZOETIS INC.: BUSINESS OVERVIEW
    • FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2020)
    • 12.1.2 MERCK & CO., INC.
    • TABLE 130 MERCK & CO., INC.: BUSINESS OVERVIEW
    • FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
    • 12.1.3 BOEHRINGER INGELHEIM GMBH
    • TABLE 131 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW
    • FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019)
    • 12.1.4 ELANCO ANIMAL HEALTH INCORPORATED
    • TABLE 132 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
    • FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2019)
    • 12.1.5 CEVA SANTE ANIMALE
    • TABLE 133 CEVA SANTE ANIMALE: BUSINESS OVERVIEW
    • 12.1.6 VIRBAC
    • TABLE 134 VIRBAC: BUSINESS OVERVIEW
    • FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2019)
    • 12.1.7 VETOQUINOL S.A.
    • TABLE 135 VETOQUINOL S.A.: BUSINESS OVERVIEW
    • FIGURE 57 VETOQUINOL S.A.: COMPANY SNAPSHOT (2019)
    • 12.1.8 DECHRA PHARMACEUTICALS PLC
    • TABLE 136 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
    • FIGURE 58 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019)
    • 12.1.9 CHANELLE PHARMA
    • TABLE 137 CHANELLE PHARMA: BUSINESS OVERVIEW
    • 12.1.10 KYORITSU SEIYAKU
    • TABLE 138 KYORITSU SEIYAKU: BUSINESS OVERVIEW
    • 12.1.11 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED
    • TABLE 139 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: BUSINESS OVERVIEW
    • FIGURE 59 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: COMPANY SNAPSHOT (2019)
    • 12.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
    • TABLE 140 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
    • 12.1.13 HIPRA
    • TABLE 141 HIPRA: BUSINESS OVERVIEW
    • 12.1.14 NORBROOK HOLDINGS LIMITED
    • TABLE 142 NORBROOK HOLDINGS LIMITED: BUSINESS OVERVIEW
    • 12.1.15 INOVET
    • TABLE 143 INOVET: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 ENDOVAC ANIMAL HEALTH
    • 12.2.2 ECO ANIMAL HEALTH GROUP PLC
    • 12.2.3 INDIAN IMMUNOLOGICALS LTD.
    • 12.2.4 ASHISH LIFE SCIENCE PVT. LTD.
    • 12.2.5 LUTIM PHARMA PVT. LTD.
  • *Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS
Back to Top
전화 문의
F A Q